PL320922A1 - Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes - Google Patents

Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes

Info

Publication number
PL320922A1
PL320922A1 PL95320922A PL32092295A PL320922A1 PL 320922 A1 PL320922 A1 PL 320922A1 PL 95320922 A PL95320922 A PL 95320922A PL 32092295 A PL32092295 A PL 32092295A PL 320922 A1 PL320922 A1 PL 320922A1
Authority
PL
Poland
Prior art keywords
somulating
mhc
molecules
prevention
bonding
Prior art date
Application number
PL95320922A
Other languages
English (en)
Inventor
Roger Pascal Lauener
Original Assignee
Om Lab Sa
Deutsche Om Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Lab Sa, Deutsche Om Arzneimittel Gmbh filed Critical Om Lab Sa
Publication of PL320922A1 publication Critical patent/PL320922A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
PL95320922A 1994-12-23 1995-12-27 Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes PL320922A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203755 1994-12-23
PCT/EP1995/005164 WO1996020215A2 (en) 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
PL320922A1 true PL320922A1 (en) 1997-11-10

Family

ID=8217495

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95320922A PL320922A1 (en) 1994-12-23 1995-12-27 Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes

Country Status (11)

Country Link
EP (1) EP0800534A2 (cs)
JP (1) JPH10511652A (cs)
CN (1) CN1171117A (cs)
AU (1) AU4347696A (cs)
BR (1) BR9510554A (cs)
CA (1) CA2208233A1 (cs)
CZ (1) CZ186897A3 (cs)
HU (1) HUT77468A (cs)
PL (1) PL320922A1 (cs)
SK (1) SK80697A3 (cs)
WO (1) WO1996020215A2 (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
CA2452986C (en) * 2001-07-02 2011-11-01 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent
WO2003064472A2 (en) * 2002-01-28 2003-08-07 Aimsco Limited Treatment of ms with goat serum
ES2232273B1 (es) * 2003-03-21 2006-07-16 Jose Manuel Fernandez-Real Lemos Nuevas aplicaciones terapeuticas de la glucoproteina cd14s.
EP2266606B1 (en) * 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (en) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Allele specific immunotherapeutic method and dosage form
GB8310403D0 (en) * 1983-04-18 1983-05-25 Mach B F Cotransformed mouse cells
JPS6225994A (ja) * 1985-05-30 1987-02-03 ジエネテイツク　システムズ　コ−ポレイシヨン Ｈｌａタイプ分け用モノクロ−ナル抗体
JPS63275526A (ja) * 1987-05-03 1988-11-14 Hiroshi Okajima Ｈｉｖウイルス中和抗体
FR2658197B1 (fr) * 1990-02-14 1992-05-22 Inst Nat Sante Rech Med Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement.
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
EP0634935A4 (en) * 1992-04-06 1996-01-31 North Shore Univ Hospital A NEW THERAPY OF SEPSIS BY MEANS OF A SOLUBLE FORM OF RECOMBINANT CD14 MYELOMONOCYTIC ANTIGEN.
ATE223485T1 (de) * 1992-10-15 2002-09-15 Toray Industries Verfahren zur herstellung von rekombinant mhcii protein in mikroorganismen
US5820858A (en) * 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Also Published As

Publication number Publication date
CN1171117A (zh) 1998-01-21
BR9510554A (pt) 1999-06-29
AU4347696A (en) 1996-07-19
WO1996020215A2 (en) 1996-07-04
SK80697A3 (en) 1997-12-10
CA2208233A1 (en) 1996-07-04
EP0800534A2 (en) 1997-10-15
HUT77468A (hu) 1998-05-28
CZ186897A3 (cs) 1998-03-18
WO1996020215A3 (en) 1996-10-10
JPH10511652A (ja) 1998-11-10

Similar Documents

Publication Publication Date Title
ZA963287B (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
PL327312A1 (en) Tricyclic amides useful in inhibiting action of g protecin and in treatment of poliferation-type diseases
HU9602583D0 (en) Gel for treatment of skin diseases and for disinfection of the skin
FI970920L (fi) Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon
AU4054297A (en) Manipulations of nitrosative and oxidatives stress in the treatment of disease
HUP9802662A3 (en) Substituted liposaccharides useful in the treatment and prevention of endotoxemia
FI950587A7 (fi) Endotoksiinimyrkytyksen ennaltaehkäisyssä ja hoidossa käyttökelpoisia menetelmiä
EP0924983A4 (en) S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
PL320922A1 (en) Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes
EP0719791A3 (en) Drugs for the treatment of restenosis and arterial sclerosis
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
IL116142A0 (en) Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
IL119459A0 (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
NO954175D0 (no) Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi
FI954138A7 (fi) Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
FI963264A7 (fi) Tromboksaani A2-välitteisten sairauksien ennaltaestoon ja hoitoon tarkoitettu aine
PL330797A1 (en) Derivatives of piperidinacetic acid and their application in treating thrombotic disorders
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
EP0893123A4 (en) MEANS OF PREVENTIVE AND CURATIVE TREATMENT OF CONDITIONS RELATED TO DIFFERENT FORMS OF AGING OF THE ORGANISM
AU3705697A (en) Proendothelin and hemoglobin in the treatment of acute hemorrhage
GB9419906D0 (en) Bnezoic amide retinoids for use in the treatment of skin diseases and cancer
AUPM932194A0 (en) Encapsulated substances and their use in the treatment of animals
GB9520159D0 (en) Benzoioc amide retinoids for use in the treatment of skin diseases and cancer